EUVIMEDEUVIMED entdecken
FallberichtOpen Access

SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly

Jessica C Ding, Benjamin A Sempowski, Lola Zerbib, Gregory T Adamson iD, Christine Insinna, Christopher M Marshall, Sanjay P Sinha iD, Audrey J Breckenridge, Rachel R Amedume, Jessica T E Johnson, Georgia L Krikorian, Natalie Dykzeul und 3 weitere

American Journal of Medical Genetics Part A · 2026-12 · 200 (12) · 2636-2648

DOI: 10.1002/ajmg.a.70224 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 15.07.2026. Verfasst von Jessica C Ding und 14 weiteren Autor:innen. Beteiligte Einrichtung: Unit on Vascular Malformations, Eunice Kennedy Shriver National Institute for Child Health and Human Development, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Chylothorax, Intracellular Signaling Peptides and Proteins, Lymphatic Abnormalities. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central conducting lymphatic anomaly (CCLA) is a devastating disorder where precision medicine can be lifesaving. Diagnosing CCLA is challenging due to its broad spectrum of symptoms, including nonimmune fetal hydrops, chylothorax, chylous ascites, or lymphedema. For that reason, genetic diagnosis is essential to uncover new genes and variants causing this debilitating disease. A patient with complex congenital heart disease presented with post‐operative refractory chylothorax. Lymphatic imaging demonstrated abnormal intercostal lymphatic perfusion consistent with CCLA and suggestive of a RASopathy, a group of genetic disorders characterized by dysregulated RAS‐MAPK signaling. Genetic testing showed a variant of uncertain significance (p.(Ala308Val)) in SHOC2, a scaffolding protein that regulates RAS‐MAPK signaling but has not yet been described in CCLA. Trametinib, a MEK1/2 inhibitor, was trialed without improvement. A conversion/extension assay was used to evaluate pathogenicity of the VUS compared to a known pathogenic variant. Zebrafish transiently expressing the wild type human SHOC2 protein or SHOC2 p.(Ala308Val) protein in the developing lymphatic and venous endothelium were used to evaluate the effect on the vasculature. Western blot was used to explore the underlying molecular mechanisms. Major to minor axis ratio was significantly increased in developing embryos injected with SHOC2 r.923c>u mRNA, indicating pathogenicity through dysregulation of MAPK/mTOR signaling. Zebrafish transiently expressing SHOC2 p.(Ala308Val) in the lymphovenous endothelium developed pericardial edema and cystic malformations of the caudal plexus and dilation of the thoracic duct. In concordance with the lack of clinical response to trametinib, immunoblot results indicate that SHOC2 p.(Ala308Val) may be inducing lymphatic malformations through non‐canonical mTOR signaling rather than dysregulated RAS‐MAPK signaling. SHOC2 is a novel cause of central conducting lymphatic anomaly. Future research should investigate the cellular and molecular mechanisms as well as therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChylothoraxIntracellular Signaling Peptides and ProteinsLymphatic AbnormalitiesAnimalsHumansMutationPyridonesPyrimidinonesTOR Serine-Threonine KinasesZebrafish

Stichwörter der Autor:innen

SHOC2central conducting lymphatic anomalytrametinibzebrafish

Substanzen

Intracellular Signaling Peptides and ProteinsPyridonesPyrimidinonesSHOC2 protein, humanTOR Serine-Threonine Kinasestrametinib

Autor:innen und Institutionen

  • Unit on Vascular Malformations, Eunice Kennedy Shriver National Institute for Child Health and Human Development, Bethesda, Maryland, USA.
  • Department of Pediatrics, Division of Pediatric Cardiology, Stanford University School of Medicine, Palo Alto, California, USA.
  • Aquaculture Core, Laboratory of Cell and Developmental Signaling, National Cancer Institute, Frederick, Maryland, USA.
  • Division of Pediatric Cardiology, University of Los Angeles Mattel Children's Hospital, Los Angeles, California, USA.
  • Department of Pediatrics, Division of Medical Genetics, Stanford University School of Medicine, Palo Alto, California, USA.

ORCID-Profile: Gregory T Adamson, Sanjay P Sinha, Sarah E Sheppard

Förderung

  • Intramural NIH HHS

Zitieren

APA

Ding, J. C., Sempowski, B. A., Zerbib, L., Adamson, G. T., Insinna, C., Marshall, C. M., Sinha, S. P., Breckenridge, A. J., Amedume, R. R., Johnson, J. T. E., Krikorian, G. L., Dykzeul, N., Floyd, B. J., Stevenson, D. A., & Sheppard, S. E. (2026). SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly. American Journal of Medical Genetics Part A, 200(12), 2636-2648. https://doi.org/10.1002/ajmg.a.70224

Vancouver

Ding JC, Sempowski BA, Zerbib L, Adamson GT, Insinna C, Marshall CM, et al. SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly. American Journal of Medical Genetics Part A. 2026;200(12):2636-2648. doi:10.1002/ajmg.a.70224

BibTeX
@article{Ding2026,
  author = {Ding, Jessica C and Sempowski, Benjamin A and Zerbib, Lola and Adamson, Gregory T and Insinna, Christine and Marshall, Christopher M and Sinha, Sanjay P and Breckenridge, Audrey J and Amedume, Rachel R and Johnson, Jessica T E and Krikorian, Georgia L and Dykzeul, Natalie and Floyd, Brendan J and Stevenson, David A and Sheppard, Sarah E},
  title = {SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly},
  journal = {American Journal of Medical Genetics Part A},
  year = {2026},
  volume = {200},
  number = {12},
  pages = {2636--2648},
  doi = {10.1002/ajmg.a.70224}
}
Kostenlos starten →